Endocrine Abstracts

Denosumab discontinuation leads to loss of bone mineral density (BMD) achieved with treatment and in some patients to multiple vertebral fractures (VFx). Beyond bone, antiresorptive agents such as denosumab may affect breast cancer biology. We report a 69-year-old woman treated with the aromatase inhibitor anastrazole for breast cancer who suffered from five spontaneous vertebral fractures after denosumab cessation. Initially, she received four years of ibandronate followed by...

Introduction: Patients successfully treated for hyperthyroidism show often the excessive weight gain and patients with hypothyroidism seldom regain their premorbid weight despite satisfactory control of their thyroid function.Aim of study: We compared the levels of hormones of ghrelin and leptin in patients with hyper and hypothyroidism, treated and untreated. We aimed to find if they play a role in a new energy balance in these patients.<p class="ab...

Objective: Fibroblast growth factor 19 (FGF-19) and FGF-21 are novel metabolic regulators that improve insulin resistence and obesity in rodents. The objective of this study was to explore whether changes in serum concentrations of FGF-19 and FGF-21 contribute to positive metabolic effects of weight loss induced by surgical treatment of obesity – sleeve gastrectomy (SG).Methods: Serum concentrations of FGF-19 and 21, adiponectin, resistin, fatty aci...